Holen Sie sich die Stockscreener-App
2.25
7.14%
0.15
Handel nachbörslich:
2.25
Schlusskurs vom Vortag:
$2.10
Offen:
$2.1199
24-Stunden-Volumen:
63,585
Relative Volume:
3.04
Marktkapitalisierung:
$22.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-17.93M
KGV:
-0.9825
EPS:
-2.29
Netto-Cashflow:
$-14.28M
1W Leistung:
+17.92%
1M Leistung:
+9.22%
6M Leistung:
-11.76%
1J Leistung:
+21.62%
1-Tages-Spanne:
$2.0205
$2.33
1-Wochen-Bereich:
$1.90
$2.33
52-Wochen-Spanne:
$1.325
$3.10
Cocrystal Pharma Inc Stock (COCP) Company Profile
Firmenname
Cocrystal Pharma Inc
Sektor
Branche
Telefon
(786) 459-1831
Adresse
19805 N. CREEK PARKWAY, BOTHELL, WA
Vergleichen Sie COCP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
2.25 | 22.89M | 0 | -17.93M | -14.28M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-07-08 | Eingeleitet | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Aktie (COCP) Neueste Nachrichten
US Penny Stocks To Watch In December 2024 - Yahoo Finance
Detection of Hydrogen Atoms Using Only 3D ED/MicroED and Contribution to Structure Determining Salts or Cocrystals - ACS Publications
Cocrystal Pharma (FRA:8CC) Price-to-Operating-Cash-Flow : (As of Dec. 04, 2024) - GuruFocus.com
Influenza Pipeline Therapeutics Assessment Report 2024 (Updated) - openPR
Hepatitis C Virus Infection Pipeline Forecast 2024: FDA - openPR
Cocrystal Pharma (STU:8CC) Earnings Yield % : N/A% (As of Nov. 26, 2024) - GuruFocus.com
Cocrystal Pharma (STU:8CC) 14-Day RSI : 67.70 (As of Nov. 20, 2024) - GuruFocus.com
Cocrystal Pharma (STU:8CC) GF Value Rank : 10 (As of Nov. 20, 2024) - GuruFocus.com
November 2024 US Exchange Standouts: Promising Penny Stocks - Yahoo Finance
Cocrystal Pharma (STU:8CC) 3-Year EPS without NRI Growth Ra - GuruFocus.com
Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - The Manila Times
Cocrystal Pharma Advances Clinical Trials Despite $4.9M Q3 Loss, Key Results Expected | COCP Stock News - StockTitan
Cocrystal Pharma Advances Antiviral Drug Development - TipRanks
Cocrystal Pharma's Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins - The Manila Times
Autonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients' 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction - The Manila Times
Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation - Yahoo Finance
Pharmaceutical Grade Hydroxytyrosol Market Poised for Growth - openPR
Innovative Approaches to Antiviral Drug Development - iHeartRadio
Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - openPR
Seasonal Influenza Treatment Market Size, Treatment Drugs, and Companies 2024 - openPR
Cocrystal Pharma execs get pay raise and stock grants By Investing.com - Investing.com Canada
Cocrystal Pharma execs get pay raise and stock grants - Investing.com India
Cocrystal Pharma Boosts Executive and Director Compensation - TipRanks
Mira Pharmaceuticals (NASDAQ:MIRA) Stock Quotes, Forecast and News Summary - Benzinga
Cocrystal Pharma commences next phase of antiviral study - Investing.com
Cocrystal Pharma commences next phase of antiviral study By Investing.com - Investing.com Canada
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts - The Manila Times
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose - EIN News
Seasonal Influenza Treatment Market Size in the 7MM was ~USD 9177 million in 2023, estimated DelveInsight - openPR
Corover Secures $4 Mn In Series A Funding Led By Venture Catalysts - BW Disrupt
K2 Principal Fund L.P. Takes $1.17 Million Position in CSLM Acquisition Corp. (NASDAQ:CSLM) - Defense World
Coherent Corp (COHR) rating reiterates by Needham - Knox Daily
Farallon Capital Management LLC Decreases Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Corcel shares drop as explorer raise funds and ups exposure in Angola - Proactive Investors USA
Cogent Communications Holdings, Inc. (NASDAQ:CCOI) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Corcel PLC Bolsters Angola Position with Increased Stake and Funding - TipRanks
Corcel (LON:CRCL) Trading 2.6% Higher - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by Rhumbline Advisers - Defense World
Bearish block trade of CSPC PHARMA(01093) 768K shares at $4.94, $3.794M turnover - AASTOCKS.com
CorVel Co. (NASDAQ:CRVL) Shares Acquired by Kayne Anderson Rudnick Investment Management LLC - MarketBeat
Coherent (COHR) Soars 6.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Momentum Is Driving Corning Stock Higher (NYSE:GLW) - Seeking Alpha
Corbus stock reiterates Outperform rating despite trial data - Investing.com
Cosmic CRF shares hit 5% upper circuit on Rs 127-crore order win; details - Business Standard
Coherent Corp (COHR)’s Market Momentum: Closing Strong at 80.98, Up 3.93 - The Dwinnex
Corning’s stock rises as it sticks to Q3 profit view - MarketWatch
COHR’s Wild Ride: Up 82.75% – What’s Next for COHR? - The InvestChronicle
Cogent Biosciences (NASDAQ:COGT) Stock Price Up 4.1% - Defense World
CorriXR Therapeutics Appoints Jill Castilla to Its Board of Directors - Morningstar
Commonwealth Equity Services LLC Has $996,000 Holdings in Compass Diversified (NYSE:CODI) - Defense World
Examining the Potential Price Growth of CoreCivic Inc (CXW) - Knox Daily
Finanzdaten der Cocrystal Pharma Inc-Aktie (COCP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):